LabTurbo Biotech

LabTurbo Biotech Financial Debt Ratio

The Financial Debt Ratio of LabTurbo Biotech (7725.TWO) as of Nov 17, 2026 is 2.03 %. In the previous year, Financial Debt Ratio was 0.78 % — a change of 161.35% (higher).

Financial Debt Ratio

2.03 %

YoY

161.35%

Last updated:

Financial Debt Ratio of LabTurbo Biotech is 2024 2.03 % . Financial Debt Ratio of LabTurbo Biotech was 2023 0.78 % . It decreases by 161.35% higher compared to the previous year.

The LabTurbo Biotech Financial Debt Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Debt Ratio
Date
Financial Debt Ratio
Jan 1, 2021
3.86 TWD
Jan 1, 2022
2.39 TWD
Jan 1, 2023
0.78 TWD
Jan 1, 2024
2.03 TWD
The LabTurbo Biotech Financial Debt Ratio history
YEARFinancial Debt RatioYoY
2.03 %+161.35%
0.78 %-67.57%
2.39 %-38.03%
3.86 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

LabTurbo Biotech Stock analysis

What does LabTurbo Biotech do? LabTurbo Biotech Corp generates revenue through its fully automated precision medical genetic testing systems and reagent kits, sold domestically and internationally. The company offers the LabTurbo AIO device for nucleic acid extraction, alongside nucleic acid extraction reagents and multi-specimen genetic testing reagents. Its testing services and sports science centers also contribute to revenue streams. Domestic and international customers purchase these products and services for medical and sports science applications. The firm's primary products are LabTurbo AIO, nucleic acid extraction reagents, and multi-specimen genetic testing reagents. These are sold to healthcare providers, laboratories, and sports science centers. The company's international sales target global healthcare markets, while domestic sales focus on Taiwan's health sector. Testing services are provided to clients seeking genetic analysis without purchasing equipment. LabTurbo Biotech Corp's revenue model combines hardware sales, consumable reagents, and service offerings. The LabTurbo AIO device is a key hardware product, while reagents represent recurring revenue through repeat purchases. Testing services cater to clients needing immediate genetic analysis, and sports science centers operate as a separate revenue stream within the company's diversified business. LabTurbo Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about LabTurbo Biotech stock

Financial Debt Ratio of LabTurbo Biotech is 2.03 % in 2024.

Financial Debt Ratio of LabTurbo Biotech changed from 0.78 % to 2.03 %, representing a 161.35% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Financial Debt Ratio LabTurbo Biotech since 2006 – with annual values, charts, and detailed analysis.

The financial debt ratio measures interest-bearing financial debt as a percentage of total assets. It isolates funded debt from trade and other non-financial obligations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Debt Ratio's LabTurbo Biotech with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — LabTurbo Biotech

All Key Metrics — LabTurbo Biotech